Lombard Odier Asset Management Europe Ltd Makes New Investment in Agilent Technologies, Inc. $A

Lombard Odier Asset Management Europe Ltd purchased a new stake in Agilent Technologies, Inc. (NYSE:A) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 38,707 shares of the medical research company’s stock, valued at approximately $5,141,000.

Several other institutional investors have also recently made changes to their positions in A. Norges Bank acquired a new stake in shares of Agilent Technologies in the 4th quarter valued at about $549,158,000. Bank of New York Mellon Corp increased its position in Agilent Technologies by 87.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after buying an additional 2,440,360 shares in the last quarter. Legal & General Group Plc acquired a new position in Agilent Technologies during the 2nd quarter worth approximately $260,101,000. AQR Capital Management LLC raised its stake in Agilent Technologies by 424.1% during the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after buying an additional 1,652,244 shares during the period. Finally, Bank of America Corp DE bought a new position in Agilent Technologies in the second quarter worth approximately $213,269,000.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 earnings of $1.62 per share, above the $1.48-$1.49 analyst consensus, while revenue of approximately $1.88 billion also exceeded expectations. EPS increased from $1.37 a year earlier, supporting the view that profitability is improving. Agilent Technologies Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year guidance following the strong quarter. Commentary highlighted product momentum, a recovery in China, improving demand and expanding margins, all of which could support additional earnings growth. Agilent Technologies Lifts Outlook After Strong Quarter
• Positive Sentiment: Several major firms raised their price targets and maintained bullish ratings after the results. Targets now range from $175 to $190, with upgrades from JPMorgan, Citi, Barclays, Goldman Sachs, Bank of America, Stifel, TD Cowen, Bernstein and RBC. Analysts Raise Agilent Technologies Price Targets
• Neutral Sentiment: Despite the improved outlook, valuation remains relatively demanding: Agilent trades at roughly 30 times earnings, with a PEG ratio above 2.7. This leaves the stock sensitive to any slowdown in demand or disappointment in future guidance.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Royal Bank Of Canada boosted their price objective on Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday. Morgan Stanley increased their target price on Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. The Goldman Sachs Group lifted their price target on shares of Agilent Technologies from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday. Jefferies Financial Group began coverage on shares of Agilent Technologies in a research note on Thursday, July 9th. They set a “hold” rating and a $135.00 price target for the company. Finally, Bank of America upped their price objective on shares of Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.33.

Agilent Technologies Stock Down 2.0%

A stock opened at $154.47 on Friday. Agilent Technologies, Inc. has a twelve month low of $108.35 and a twelve month high of $163.75. The company has a quick ratio of 1.62, a current ratio of 2.05 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average is $140.30 and its 200-day moving average is $127.04. The firm has a market capitalization of $43.63 billion, a PE ratio of 30.41, a P/E/G ratio of 2.72 and a beta of 1.25.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The company had revenue of $1.88 billion for the quarter, compared to analysts’ expectations of $1.84 billion. During the same quarter in the previous year, the firm earned $1.37 earnings per share. Agilent Technologies’s quarterly revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Sell-side analysts expect that Agilent Technologies, Inc. will post 6.2 EPS for the current fiscal year.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.